Every Spin-Off
Samsung Epis Holdings
0126Z0 KSCompletedKRHolding company that owns Samsung Bioepis, which develops and makes biosimilar copies of biologic drugs (for immune diseases, cancer and eye disease) sold worldwide mostly through partners.
Samsung Biologics spun off its biosimilar holdings (100% of Samsung Bioepis plus new investments) into Samsung Epis Holdings via a 인적분할 at 0.6503913:0.3496087, keeping the CDMO business, with the new holding company re-listed on KOSPI.
- Distribution date
- 24 Nov 2025
- Structure
- Spin-off
- Parent
- Samsung Biologics (207940 KS)
- Spin-off ticker
- 0126Z0 KS
- Listing
- KOSPI
- Market
- South Korea
- Sector
- Health care
- Size
- mid
Source documents
- Press releaseSamsung Biologics EGM approves split; re-listing 24 Nov (10/17/25)
- PresentationNot located
- Prospectus / demerger documentNot located
- Sourcemydailybyte.com (debut day, 11/25)
- Sourcedealsite.co.kr (ratio and timeline, 05/22/25)
- Sourcekormedi.com (schedule change)
Every Spin-Off research
No report on this situation yet. New reports are published on Substack first.
Receive reports by email